ibutamoren-mesylate and Parkinson-Disease

ibutamoren-mesylate has been researched along with Parkinson-Disease* in 1 studies

Reviews

1 review(s) available for ibutamoren-mesylate and Parkinson-Disease

Article	Year
The aging process: where are the drug opportunities? Current opinion in chemical biology, 2000, Volume: 4, Issue:4 New data support a role for growth hormone secretagogue receptor agonists as rejuvenating agents. Two enzymes critical for the formation of beta-amyloid plaques in Alzheimer's disease have been identified. Estrogen receptor beta continues to emerge as a potential drug target. The orphan nuclear receptor Nurr1 appears to be a target for treatment of Parkinson's disease, and propargylamines are emerging as inhibitors of oxidative damage in neurons. Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amyloid; Animals; Antiparkinson Agents; Brain; DNA-Binding Proteins; Humans; Indoles; Monoamine Oxidase Inhibitors; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinson Disease; Rats; Receptors, Estrogen; Spiro Compounds; Transcription Factors	2000

Article

Year

The aging process: where are the drug opportunities?

Current opinion in chemical biology, 2000, Volume: 4, Issue:4

New data support a role for growth hormone secretagogue receptor agonists as rejuvenating agents. Two enzymes critical for the formation of beta-amyloid plaques in Alzheimer's disease have been identified. Estrogen receptor beta continues to emerge as a potential drug target. The orphan nuclear receptor Nurr1 appears to be a target for treatment of Parkinson's disease, and propargylamines are emerging as inhibitors of oxidative damage in neurons.

Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amyloid; Animals; Antiparkinson Agents; Brain; DNA-Binding Proteins; Humans; Indoles; Monoamine Oxidase Inhibitors; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinson Disease; Rats; Receptors, Estrogen; Spiro Compounds; Transcription Factors

2000